DPP-4 exists as both a membrane-bound and soluble form. DPP-4 has historically been associated with its capacity to metabolize incretin hormones. Recent studies have identified additional functions of ...

In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Fecal dipeptidyl peptidase-4 may be used as a ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

This study evaluates the long-term cost-effectiveness of treatment involving combination therapy with dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors ...

Findings from a study published in Acta Diabetologica support that treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors is associated with better vitamin D balance in patients with type 2 diabetes ...

The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on the risk of heart failure in patients with type 2 diabetes is uncertain, based on low quality of evidence found in a systematic review and ...

FDA has warned that the drug class dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling. In a statement, the FDA said said it had issued a "warning and ...

New data for Jardiance, an SGLT2 diabetes therapy marketed by Lilly, could cause a fundamental shift in how doctors treat type-2 diabetes, leading them to change their prescribing habits at the second ...

Among people with type 2 diabetes, new treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor was linked with higher risk of a rare blistering skin condition, researchers reported. Compared with ...